Table 2 Best response to nivolumab (RECIST v 1.1) based on RCC histology
From: Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Histology | N | PR | SD | PD | Non-evaluable |
|---|---|---|---|---|---|
Papillary | 16 | 2 (14%) | 3 (21%) | 9 (64%) | 2 |
Unclassified | 14 | 4 (36%) | 3 (27%) | 4 (36%) | 3 |
Chromophobe | 5 | 0 (0%) | 3 (75%) | 1 (25%) | 1 |
Collecting Duct | 4 | 1 (25%) | 0 (0%) | 3 (75%) | 0 |
MTSCC | 1 | 0 (0%) | 1 (100%) | 0 (0%) | 0 |
Translocation | 1 | 0 (0%) | 0 (0%) | 1 (100%) | 0 |
All Histologies | 41 | 7 (20%) | 10 (29%) | 18 (51%) | 6 |